Apolipoprotein E Dynamics in Alzheimer's Disease Pathophysiology

Apolipoprotein E (apoE) is a lipid‐binding protein with three major human isoforms (ε2, ε3 and ε4) that profoundly influence the risk, onset and progression of Alzheimer’s disease (AD). In the central nervous system, apoE produced by astrocytes and microglia mediates cholesterol redistribution, synaptic repair and clearance of amyloid-β (Aβ) peptides. The ε4 isoform heightens aggregation of Aβ into plaques, fosters tau hyperphosphorylation and impairs lipid homeostasis, whereas ε2 offers relative protection. Isoform-specific interactions with glial receptors, blood–brain barrier integrity and intracellular signalling pathways shape divergent neuroinflammatory profiles and neuronal resilience. Recent advances reveal how apoE4 modulates lipid droplet formation in microglia, alters tight junction dynamics at the cerebrovascular endothelium and influences the cellular milieu that precipitates synaptic dysfunction. A deeper grasp of apoE dynamics offers routes to genotype-tailored interventions aimed at restoring lipid flux, reducing neurotoxicity and rebalancing protective functions lost in AD.

Research from Nature Portfolio

Recent work has identified a microglial subpopulation in APOE4/4 carriers characterised by accumulation of lipid droplets and upregulation of the acyl-CoA synthetase ACSL1. In human‐derived models, fibrillar Aβ drives triglyceride synthesis and droplet formation in an apoE-dependent manner, while secreted factors from lipid-laden microglia promote tau phosphorylation and neuronal injury. Complementary studies of a rare R136S (Christchurch) variant demonstrate dose-dependent protection against apoE4-driven tauopathy, neurodegeneration and inflammatory glial states, highlighting molecular pathways that may be harnessed to neutralise toxic gain-of-function. Foundational population data further underscore that individuals homozygous for the APOE2 allele exhibit an exceptionally low odds ratio for Alzheimer’s dementia, emphasising the impact of apoE genotype on disease susceptibility and pointing to protective mechanisms for therapeutic exploitation.

Apolipoprotein E Dynamics in Alzheimer's Disease Pathophysiology publication trend

The graph below shows the total number of articles in apolipoprotein e dynamics in alzheimer's disease pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Apolipoprotein E (apoE): A lipoprotein that transports cholesterol and phospholipids in the brain, with three major human genetic variants (ε2, ε3, ε4).

Isoform: One of several structurally related forms of a protein arising from genetic polymorphism or alternative splicing.

Microglia: Innate immune cells of the central nervous system that clear debris, secrete cytokines and modulate synaptic connectivity.

Lipid droplet: Intracellular organelles composed of neutral lipids, involved in energy storage and cellular lipid homeostasis.

Tau pathology: Abnormal aggregation and hyperphosphorylation of the microtubule-associated protein tau, leading to neurofibrillary tangles.

Neuroinflammation: Activation of glial cells and immune pathways in the brain, often associated with cytokine release and neuronal stress.

References

1. APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia. Nature (2024).
2. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nature Neuroscience (2023).
3. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications (2020).
4. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Molecular Neurodegeneration (2022).
5. Apolipoprotein E Regulates the Integrity of Tight Junctions in an Isoform-dependent Manner in an in Vitro Blood-Brain Barrier Model*. Journal of Biological Chemistry (2011).